UPDATE 4-Novartis $2 mln gene therapy for rare disorder is world's most expensive drug
May 24, 2019 at 15:55 PM EDT
ZURICH/NEW YORK, May 24 - Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million.
